Until recently, it's been unclear whether accountable care organizations can live up to the hype or are just a passing healthcare reform fad.
Some people used to say that accountable care organizations (ACOs) are like unicorns—they sound amazing but nobody has seen one in real life. However, with hundreds of ACOs now sprouting up in an array of shapes and sizes in Medicare, Medicaid, and the commercial sector, this saying has finally been put to rest.
Still, until recently, it’s been unclear whether ACOs can live up to the hype or are just a passing healthcare reform fad. Although the results are preliminary, the experiences of Medicaid ACO programs in Colorado, Minnesota, and Oregon show that this model of coordinating care—and then sharing in the resulting savings with payers—holds real promise.
Read more at The Commonwealth Fund: http://bit.ly/1B8PYeA
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More